These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises. Gorlin DI Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385 [No Abstract] [Full Text] [Related]
9. Drug patent protection: how long is long enough? Sibbald B CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146 [No Abstract] [Full Text] [Related]
10. International patent protection for HIV-related therapies: patent attorney's perspective. Pavento LC; Greene JL; McDonald JK Emory Int Law Rev; 2003; 17(2):919-31. PubMed ID: 15199935 [No Abstract] [Full Text] [Related]
11. Patent infringement. Generic HIV drugmaker's patent claim is time-barred. AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916 [No Abstract] [Full Text] [Related]
12. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering. Paine CS Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807 [No Abstract] [Full Text] [Related]
13. A day late and a few million dollars short. Goldenson D Nat Biotechnol; 2009 Jun; 27(6):538-41. PubMed ID: 19513055 [TBL] [Abstract][Full Text] [Related]
14. [Novartis should discontinue its patent case in India!]. PehrOlov P Lakartidningen; 2007 Feb 14-20; 104(7):524. PubMed ID: 17375688 [No Abstract] [Full Text] [Related]
15. Patent watch. Harrison C Nat Rev Drug Discov; 2008 Nov; 7(11):882-3. PubMed ID: 18974746 [No Abstract] [Full Text] [Related]
16. Pharmaceutical patent life-cycle management after KSR v. Teleflex. Furrow ME Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462 [No Abstract] [Full Text] [Related]
17. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity. Fernandez DS; Huie JT Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155 [No Abstract] [Full Text] [Related]
19. Pharmaceutical patent settlements: the antitrust risks. Balto DA Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464 [No Abstract] [Full Text] [Related]
20. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related] [Next] [New Search]